Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
ICE says ARM share of mortgage rate locks nears 4-year high as 30-year fixed hits 7.2%

ICE says ARM share of mortgage rate locks nears 4-year high as 30-year fixed hits 7.2%

BitgetBitget2026/10/05 13:04

ICE Mortgage Monitor flagged renewed adjustable-rate mortgage demand as rising fixed rates pushed ARM share above 11% of rate locks. ICE’s Conforming 30-year Fixed Rate Index hit 7.2% on Sept. 24, lifting borrower interest in lower initial ARM payments. Active first-lien ARMs rose to 3.1 million, the highest in 5.5 years, though they remain 5.6% of active mortgages. Only 1.05 million ARMs have reached their first reset, the lowest in more than 25 years, limiting near-term payment shock. About 74,000 7-year ARMs from 2020 are set to reset in 2027, with a median payment increase of USD 1,066. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ICE - Intercontinental Exchange Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610050900BIZWIRE_USPR_____20261005_BW722684) on October 05, 2026, and is solely responsible for the information contained therein.

  • ICE Mortgage Monitor flagged renewed adjustable-rate mortgage demand as rising fixed rates pushed ARM share above 11% of rate locks.
  • ICE’s Conforming 30-year Fixed Rate Index hit 7.2% on Sept. 24, lifting borrower interest in lower initial ARM payments.
  • Active first-lien ARMs rose to 3.1 million, the highest in 5.5 years, though they remain 5.6% of active mortgages.
  • Only 1.05 million ARMs have reached their first reset, the lowest in more than 25 years, limiting near-term payment shock.
  • About 74,000 7-year ARMs from 2020 are set to reset in 2027, with a median payment increase of USD 1,066.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ICE - Intercontinental Exchange Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610050900BIZWIRE_USPR_____20261005_BW722684) on October 05, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.

Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.

华尔街见闻•2026/10/26 05:56
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.

A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

智通财经•2026/10/26 04:20
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.